{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:35:26Z","timestamp":1771475726723,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.msard.2020.101957","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:53:06Z","timestamp":1579521186000},"page":"101957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Satisfaction and adherence with glatiramer acetate 40mg\/mL TIW in RRMS after 12 months, and the effect of switching from 20mg\/mL QD"],"prefix":"10.1016","volume":"40","author":[{"given":"Gary","family":"Cutter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Veneziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Grinspan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahir","family":"Al-Banna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Boyko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Maida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija Bosnjak","family":"Pasic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Everts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Cordioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2020.101957_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1191\/1352458503ms945oa","article-title":"Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis","volume":"9","author":"Achiron","year":"2003","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.101957_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"3","key":"10.1016\/j.msard.2020.101957_bib0003","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.64","volume":"49","author":"Comi","year":"2001","journal-title":"Ann. Neurol."},{"issue":"20","key":"10.1016\/j.msard.2020.101957_bib0004","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.101957_bib0010","unstructured":"Copaxone\u00ae (glatiramer acetate) [prescribing information]. Overland Park, KS: Teva Neuroscience, Inc.; January 2018."},{"key":"10.1016\/j.msard.2020.101957_bib0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","article-title":"Patient-reported outcomes in relapsing forms of MS: real-world, global treatment experience with teriflunomide from the Teri-PRO study","volume":"17","author":"Coyle","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.101957_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418774338","article-title":"Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial","volume":"11","author":"Cree","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.101957_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.msard.2019.04.036","article-title":"Higher satisfaction and adherence with glatiramer acetate 40mg\/mL TIW vs 20mg\/mL QD in RRMS","volume":"33","author":"Cutter","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2020.101957_bib0008","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/1756285610385608","article-title":"Evolving expectations around early management of multiple sclerosis","volume":"3","author":"Gold","year":"2010","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2020.101957_bib0009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"3","key":"10.1016\/j.msard.2020.101957_bib0011","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3111\/13696998.2012.667027","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US","volume":"15","author":"Ivanova","year":"2012","journal-title":"J. Med. Econ."},{"issue":"7","key":"10.1016\/j.msard.2020.101957_bib0012","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.101957_bib0013","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.23938","article-title":"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"73","author":"Khan","year":"2013","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2020.101957_bib0014","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.101957_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.7224\/1537-2073.2016-039","article-title":"Preferences for multiple sclerosis treatments: using a discrete-choice experiment to examine differences across subgroups of us patients","volume":"19","author":"Mansfield","year":"2017","journal-title":"Int. J. MS Care"},{"issue":"2","key":"10.1016\/j.msard.2020.101957_bib0014a","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.101957_bib0016","unstructured":"Ritvo, P.G., Fischer, J.S., Miller, D.M., Andrews, H., Paty, D.W., LaRocca, N.G., 1997. Multiple sclerosis quality of life inventory: a user's manual. The Consortium of Multiple Sclerosis Centers, Heath Services Research Subcommittee."},{"issue":"1","key":"10.1016\/j.msard.2020.101957_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12325-010-0093-7","article-title":"Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis","volume":"28","author":"Tan","year":"2011","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.msard.2020.101957_bib0018","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00415-009-0096-y","article-title":"Factors that influence adherence with disease-modifying therapy in MS","volume":"256","author":"Treadaway","year":"2009","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.101957_bib0019","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/1352458516657441","article-title":"Measuring treatment satisfaction in MS: is the treatment satisfaction questionnaire for medication fit for purpose?","volume":"23","author":"Vermersch","year":"2017","journal-title":"Mult. Scler."},{"issue":"1\u20133","key":"10.1016\/j.msard.2020.101957_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","article-title":"Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients","volume":"118","author":"Vernon","year":"2010","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.msard.2020.101957_bib0021","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2196\/jmir.1687","article-title":"Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)","volume":"13","author":"Wicks","year":"2011","journal-title":"J. Med. Internet Res."},{"issue":"1\u20132","key":"10.1016\/j.msard.2020.101957_bib0022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2014.06.030","article-title":"Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices","volume":"344","author":"Wilson","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2020.101957_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.msard.2015.06.005","article-title":"GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis","volume":"4","author":"Wolinsky","year":"2015","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:16Z","timestamp":1761900616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":24,"alternative-id":["S221103482030033X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.101957","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Satisfaction and adherence with glatiramer acetate 40mg\/mL TIW in RRMS after 12 months, and the effect of switching from 20mg\/mL QD","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.101957","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101957"}}